Eli Lilly has inked a deal with Bangladesh’s International Agencies (IABL) to supply active pharmaceutical ingredient (API) for its human insulin at an undisclosed "reduced price," the Indianapolis-based drugmaker said. The move is part of a bid to increase access and improve insulin affordability for nearly 1 million people with diabetes in Bangladesh by 2030.

Under the accord, IABL will be tasked with the formulation and fill-finish of human insulin vials and cartridges, which will roll out under the company’s trademark and brand by 2025. The product will be exclusively available in Bangladesh, Lilly pointed out in a press release.

The deal marks Lilly’s second recent collaboration under the company’s 30x30 initiative, which seeks to improve healthcare access for 30 million people in limited-resource settings, annually, by 2030.